



MARKET ACCESS RADAR

USER MANUAL
2021

MARKETACCESS-RADAR.COM

MARKET ACCESS RADAR



MARKET ACCESS | REIMBURSEMENT | EVIDENCE

YOUR MARKET ACCESS REPOSITORY

ORDER ACCESS

SCROLL FOR MORE



ABOUT

600

Sources


36,121

Records in total

2,168

Report Editions

CURRENT COVERAGE OF COUNTRIES



- 1 ABOUT MAR
- 2 DAILY BRIEF
- 3 ARCHIVE & SEARCH
- 4 DASHBOARD
- 5 PORTAL PROFILES & MY RADAR
- 6 REPORT
- 7 CONTACT

ABOUT MAR

Due to a strongly competitive environment and existing legal restrictions in local and international markets, activities related to reimbursement require excellent knowledge of all risks and opportunities occurring in the selected markets. Such knowledge is attained by gathering relevant information from various sources.

MAR: Quick and Easy Access to MA Information

Market Access Radar (MAR) is a **repository** of more than 8 years of daily delivery of the most up-to-date market access (MA)-related news and reports, hand-picked by experts in reimbursement. The service is available as an online repository (marketaccess-radar.com) with search engines and advanced user profiles which enable customized data flow under user specifications: country/category filters, tags, and daily or weekly reports.

MAR combines the assistance of local MA experts and web monitoring. MAR's rooted experts who assess and prepare relevant data daily. This ensures that users receive MA-related information of the highest quality and importance.

More than 600 international news sources are being monitored daily by our experts.

FULLY CUSTOMIZED BY THE USER

ABOUT MAR

HOMEPAGE

DAILY BRIEF

ARCHIVE

MY RADAR

MY DASHBOARD

The screenshot shows the MAR homepage interface. At the top, there is a navigation bar with the 'MARKET ACCESS RADAR' logo on the left, a search bar, and an 'Ask the expert' button on the right. Below the navigation bar is a secondary bar with links to 'Daily Brief', 'Bookmarks', 'My Tags', 'My Alerts', and 'Most Popular'. A 'MY DASHBOARD' button is also present on the right side of this bar.

The main content area is divided into several sections:

- Daily Brief 2021-10-19:** This section displays a list of records. The first record is titled 'Germany: IQWiG completes assessment according to §35a Social Code Book V of stereotactic radiosurgery in the treatment of vestibular schwannomas'. It includes a link to the assessment and tags for 'GERMANY', 'IQWiG', 'BENEFIT ASSESSMENT', and 'STEREOTACTIC RADIOSURGERY'. The second record is titled 'Germany: IQWiG completes assessment according to §35a Social Code Book V of Empagliflozin in the treatment of heart failure'. It includes a link and tags for 'GERMANY', 'IQWiG', 'BENEFIT ASSESSMENT', and 'HEART FAILURE'. The third record is titled 'Germany: IQWiG completes assessment according to §35a Social Code Book V of Tralokinumab in the treatment of atopic dermatitis'. It includes a link and tags for 'GERMANY', 'IQWiG', 'BENEFIT ASSESSMENT', and 'TRALOKINUMAB'. Each record has a 'SHOW RELATED RECORDS (1)' link.
- Your Regional Interest:** This section features a world map with blue dots indicating regions of interest.
- Market Access Catalyst:** This section lists recent news items under the heading 'Safety'. The items include:
 - 19 Oct 2021:** Australia: A discussion paper on the potential for mandatory reporting of medical device adverse events by healthcare facilities in Australia has been published by GOV.
 - 14 Oct 2021:** PRAC, after the examination, concluded that medicines containing Posaconazole with the use of all-trans retinoic acid might provoke hyperkalemia. Therefore, PRAC considered it vital to monitor side effects when using ATRA, and the instructions for medical use of medicines containing Posaconazole should be amended accordingly.
 - 11 Oct 2021:** Global: Allogene's revelation that chromosomal abnormalities were detected in the allogeneic Car-T cells infused into a lymphoma patient raises the possibility that gene editing in manufacturing the cells could disrupt their genome and make them capable of causing serious damage. A lymphoma patient in the Alpha-2 trial of the CD19-directed allogeneic Car-T project ALLO-501A was found to have ALLO-501A cells.
- My tags:** This section displays a list of tags under the heading 'MIGRAINE'. The tags include:
 - 04 Oct 2021:** USA: FDA grants approval to Qulipta (atogepant) for the prevention of episodic migraine in adults.
 - 10 Sep 2021:** Global: Teva's Ajovy loses against Biohaven/AbbVie migraine meds in meta-analysis.
 - 06 Sep 2021:** US: FDA has approved Trudhesa (dihydroergotamine mesylate, Impel NeuroPharma) for the acute treatment of migraine with or without aura in adults.
 - 19 Aug 2021:** Global: Phase III trial results of Intranasal Dihydroergotamine Safe for the acute treatment of migraine.
 - 04 Aug 2021:** Germany: IQWiG publishes Benefit assessment according to §35a Social Code Book V for erenumab in the treatment of pretreated and treatment-naïve patients with at least 4 migraine days per month who are candidates for conventional migraine prophylaxis (biorepopulation of the approved therapeutic indication).

At the bottom right of the screenshot, there is a calendar for October 2021, showing the dates from Sunday to Saturday. The date 19 is highlighted in blue.

ABOUT MAR

TYPICAL DATA ENTRY

Records are typical data entries in our repository.



1

The Transparency Council considers it unjustified to reimburse Trulicity (dulaglutide) in the indication: type 2 diabetes, after failure of treatment of at least two oral hypoglycaemic drugs or basal insulin in combination with at least one oral hypoglycaemic drug, with insufficiently controlled diabetes, with BMI level $\geq 30 \text{ kg / m}^2$ and a very high cardiovascular risk. The Council considers that the reimbursement of diabetes mellitus type 2, in patients using at least two oral hypoglycemic drugs or basal insulin in combination with at least one oral hypoglycemic drug, with HbA1c $\geq 8\%$, with obesity defined as BMI $\geq 30 \text{ kg / m}^2$, is REQUIRED by the Council and with a very high cardiovascular risk. The Council proposes to introduce such RSS for GLP-1 analogues in order to bring their price closer to the flozyn group



4

2

<https://bipold.aotm.gov.pl/index.php/zlecenia-m>

3

POLAND TRANSPARENCY COUNCIL TRULICITY DULAGLUTIDE
DIABETES MELLITUS TYPE 2 NEGATIVE OPINION AHTAPOL

1

LEAD

The main part of a record is the lead, reflecting the idea of maximum information with the minimum content.

2

SOURCE

The link is the source of the original news story. To go to the source, click on the link.

3

TAG

Each record is assigned to a specific tag. Click on a tag to open a new window inside the database. The user can see all the information gathered under the given tag.

The user can also assign it to his/her **favorite tags** or **alerts**.

● orphan drugs ADD TO MY TAGS ADD TO MY ALERTS

4

BOOKMARK

The user can easily go back to the record of interest by clicking on the icon and bookmarking it.

ABOUT MAR

TYPICAL DATA ENTRY



The Transparency Council considers it unjustified to reimburse Trulicity (dulaglutide) in the indication: type 2 diabetes, after failure of treatment of at least two oral hypoglycaemic drugs or basal insulin in combination with at least one oral hypoglycaemic drug, with insufficiently controlled diabetes, with BMI level ≥ 30 kg / m² and a very high cardiovascular risk. The Council considers that the reimbursement of diabetes mellitus type 2, in patients using at least two oral hypoglycemic drugs or basal insulin in combination with at least one oral hypoglycemic drug, with HbA1c $\geq 8\%$, with obesity defined as BMI ≥ 30 kg / m², is REQUIRED by the Council and with a very high cardiovascular risk. The Council proposes to introduce such RSS for GLP-1 analogues in order to bring their price closer to the flozyn group



<https://bipold.aotm.gov.pl/index.php/zlecenia-m>

POLAND TRANSPARENCY COUNCIL TRULICITY DULAGLUTIDE
DIABETES MELLITUS TYPE 2 NEGATIVE OPINION AHTAPOL

ASK AN EXPERT

If the user needs more information about the given record, whether concerning the local market or due to the need for additional analysis, click on the icon to speak to one of our experts. Each record contains this option.



ASK THE EXPERT

Get in touch with your team of local Experts.
Do You have any questions? Our Experts will be happy to help

Selected subject

The Transparency Council considers it unjustified to reimburse Trulicity (dulaglutide) in the indication: type 2 diabetes, after failure of treatment of at least two oral hypoglycaemic drugs or basal insulin in combination with at least one oral hypoglycaemic drug, with insufficiently controlled diabetes, with BMI level ≥ 30 kg / m² and a very high cardiovascular risk. The Council considers that the reimbursement of diabetes mellitus type 2, in patients using at least two oral hypoglycemic drugs or basal insulin in combination with at least one oral hypoglycemic drug, with HbA1c $\geq 8\%$, with obesity defined as BMI ≥ 30 kg / m², is REQUIRED by the Council and with a very high cardiovascular risk. The Council proposes to introduce such RSS for GLP-1 analogues in order to bring their price closer to the flozyn group

Question


Ask question...

An Expert from our team will be in touch in 24h with more information or to schedule a personal Teleconference

SEND

ABOUT MAR

Some records have their own history. The related records function allows the user to see archived records regarding the topic at hand.



EU: EMA has started evaluating an application to extend the use of BioNTech/Pfizer's COVID-19 vaccine, Comirnaty, to children aged 5 to 11

<https://www.ema.europa.eu/en/news/ema-starts>

EU EMA COMIRNATY COVID-19 PFIZER BIONTECH VACCINES

HIDE RELATED RECORDS (83)

EU: EMA has started evaluating an application to extend the use of BioNTech/Pfizer's COVID-19 vaccine, Comirnaty, to children aged 5 to 11

<https://www.ema.europa.eu/en/news/ema-starts>

EU EMA COMIRNATY COVID-19 PFIZER BIONTECH VACCINES

HIDE RELATED RECORDS (83)

19 Oct 2021

Finland: The use of the AstraZeneca Vaxzevria coronavirus vaccines will end in Finland when the current Vaxzevria vaccines expire on 30 November, 2021. After this the vaccine will not be procured for Finland. Before their expiration, the vaccine will still be available as before for second and third vaccine dose. At present, the AstraZeneca vaccines are being offered only to those over the age of 65

18 Oct 2021

The Ministry of Health of Russia issued a permit to conduct CTs of a vaccine against COVID-19—Betuvax-Cov-2. The first and second phases of CTs will be held from Sep 27 to Aug 31, 2022, based on the St. Petersburg Research Institute of Influenza n.a. Smorodintsev, Medical Center of Eco-Safety and the Perm Center for Professional Medicine

13 Oct 2021

Argentina: Argentina received 960,400 doses of AstraZeneca vaccines, donated by Spain

12 Oct 2021

Brazil: 1.9 million doses from Pfizer arrive in Brazil

08 Oct 2021

France: HAS publishes guidelines on Comirnaty (mRNA vaccine) booster dose in COVID-19

08 Oct 2021

USA: Pfizer files for FDA authorisation of COVID-19 vaccine booster dose in Kids Aged 5 to 11

06 Oct 2021

USA: Johnson & Johnson to seek FDA approval for COVID-19 vaccine booster shot

06 Oct 2021

Norway: The Government decides to offer booster doses of COVID-19 vaccine to the elderly and nursing home residents, following NIPH assessment

05 Oct 2021

ABOUT MAR

NAVBAR



Search OPTIONS ← Search engine ([more](#))



- ← User Settings and MAR customization, including:
- Portal Profile ([more](#))
 - Report Settings ([more](#))
 - Change Password
 - Help (user manual)
 - Logout



Ask the expert

← Expert Advice (general question(s))



ASK THE EXPERT

Get in touch with your team of local Experts.
Do You have any questions? Our Experts will be happy to help

Question

Ask question...

An Expert from our team will be in touch in 24h with more information or to schedule a personal Teleconference

SEND

If the user needs additional analysis, not related to the record, simply click on the icon to speak to our experts. An expert from our team will be in touch within 24h with more information or to schedule a personal teleconference.

DAILY BRIEF

The Daily Brief is a **feature** that shows the most recent records added to our repository.



ARCHIVE

MY RADAR

Daily Brief

Bookmarks

My Tags

My Alerts

Most Popular

FROM 18 Oct 2021 TO 18 Oct 2021 clear



Daily Brief 2021-10-18

Total 10 records.

Selected countries: ALL

Selected categories: ALL

ASK
AN EXPERT

US: Roche announced that FDA has approved Tecentriq (atezolizumab) as adjuvant treatment, following surgery and platinum-based chemotherapy, for adults with Stage II-IIIa non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-approved test

<https://www.globenewswire.com/news-release/>

ROCHE

USA

NSCLC

NON-SMALL CELL LUNG CANCER

TECENTRIQ

ATEZOLIZUMAB

SHOW RELATED RECORDS (1)

ASK
AN EXPERT

The Transparency Council considers it justified to reimburse Mizetam (Ezetimibe Atorvastatin) in all registered indications as at the date of the decision, i.e. supportive treatment for use along with the diet in adult patients with primary hypercholesterolemia (heterozygous and homozygous family and non-family) or mixed hyperlipidemia already controlled with atorvastatin and ezetimibe, which are administered in the same doses as drugs available in a prescription pharmacy, within the existing limit group and dispensed for a fee of 30%, provided that their price for the patient will be comparable or lower than the sum of the prices medicines containing separate active substances included in the proposed drug

<https://bipold.aotm.gov.pl/index.php/zlecenia-m>

POLAND

POSITIVE OPINION

TRANSPARENCY COUNCIL

MIZETAM

EZETIMIBE


ATORVASTATIN

AHTAPOL


HYPERLIPIDEMIA

HYPERCHOLESTEROLEMIA

DAILY BRIEF




All of the user's saved records as bookmarks




The user can unselect records from the bookmark list by clicking the bookmark icon.

The list of the user's favorite tags



The user can see all of the records from tags marked as favorites.

The list of the user's tags, marked with alert function



For each of the selected tags, marked as alert, we will send an additional alert email announcement if something new appears in our repository.



The date checkbox has multiple uses. Upon logging into MAR, Daily Brief indicates the current issue. In this field, the user can freely search the database while using the search engine, My Radar, or Archive.

Changing the date range also affects the information displayed on My Dashboard.

When the date filter is active, the “clear” button appears, which enables the user to clear the selected date.

When using the search engine, it automatically indicates the maximum time range for which search results are available. The user can change these any time using the date checkbox.



You can easily filter Records in daily brief, archive, and My Radar, **by Records categories**


DAILY BRIEF

The user can easily filter records in Daily Brief, My Radar, and Archive **by country (or region)** by selecting the country of interest on the interactive map **or** by using the filter option.

Your Regional Interest

+

-



FILTER BY REGION/COUNTRY

Select regions

GLOBAL	ASIA	EUROPE	NORTH AMERICA
SOUTH AMERICA	AUSTRALIA	AUSTRIA	BELARUS
BELGIUM	BOSNIA AND HERZEGOVINA	BRAZIL	BULGARIA
CANADA	CHINA	CROATIA	CYPRUS
CZECH REPUBLIC	DENMARK	ESTONIA	FRANCE
GERMANY	GREECE	HUNGARY	INDIA
IRELAND	ITALY	JAPAN	KAZAKHSTAN
LATVIA	LITHUANIA	MONTENEGRO	NETHERLANDS
NEW ZEALAND	NORWAY	POLAND	ROMANIA
RUSSIA	SERBIA	SLOVAKIA	SLOVENIA
SPAIN	SWEDEN	SWITZERLAND	TURKEY
UK	UKRAINE	USA	

DESELECT ALL

SELECT ALL

APPLY

DAILY BRIEF

The user's active filters appear here



● Daily Brief 2021-10-19

Total **9** records.

Selected countries: USA, CANADA, BRAZIL, AUSTRALIA, BELGIUM, CHINA, HUNGARY

Selected categories: ALL

CATEGORIES OF RECORDS

- APPROVAL
- SAFETY
- PIPELINE
- EVIDENCE
- REIMBURSEMENT
- ECONOMY
- INDUSTRY
- LAW
- PATENTS
- PEOPLE
- **HOT CATEGORY**

The “Hot” indicated in red is a category that consists only of records with global hot topics, e.g., only news tagged as Covid-19.

ADDITIONAL INFORMATION

« October 2021 »						
Su	Mo	Tu	We	Th	Fr	Sa
26	27	28	29	30	1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31	1	2	3	4	5	6

The user can easily select previous Daily Reports, indicated in green underline, by viewing the calendar in My Dashboard. Select a date in the calendar and a historical Daily Brief will be shown.

ARCHIVE AND SEARCH

Search OPTIONS

The search engine can be used to search the Archive, both by the tags assigned to the record and by its content. The user can enter any query, or use existing phrase suggestions (based on tags), combined into a query.

Search results are shown after the user confirms the selected phrases and pressing the Enter key.

Note that as the phrases are approved, the date ranges change. This happens automatically and indicates to the user in what maximum time range the data contained in the query content appears in the database. By changing the date range manually, the user has the possibility of introducing additional filtering into the search results. To exit the results presentation mode, click on any portal element (e.g., Daily Brief).

Toggle buttons allow for more advanced searching by enabling/disabling type and scope.

DEFAULT SEARCH OPTIONS

Search type

☒ AND

☐ OR

Search scope

☒ ALL

☐ Only in tags

☐ Only in leads

SAVE

EXPORT RESULTS

● Search results for: FDA,adalimumab

Total 7 records

Selected countries: USA, CANADA, BRAZIL, AUSTRALIA, BELGIUM, CHINA, HUNGARY

Selected categories: ALL



19 Oct 2021

US: FDA approved the first interchangeable biosimilar product to treat certain inflammatory diseases. Cyltezo (adalimumab-adbm), originally approved in August 2017, is both biosimilar to, and interchangeable with (may be substituted for), its reference product Humira (adalimumab) for Cyltezo's approved uses. Cyltezo is the second interchangeable biosimilar product approved by the agency and the first interchangeable monoclonal antibody. Once on the market, approved biosimilar and interchangeable biosimilar products can play a role in facilitating access to treatments for many serious health conditions. Cyltezo is approved for the following indications in adult patients: moderately to severely active rheumatoid arthritis; active psoriatic arthritis; active ankylosing spondylitis; moderately to severely active Crohn's disease; moderately to severely active ulcerative colitis; and moderate to severe chronic plaque psoriasis

<https://www.fda.gov/news-events/press-announ>


The archive contains over

38 000 INT + CEE

Records


from 20/08/2012

DASHBOARD




DASHBOARD

The Dashboard allows the user to quickly view a few of the most current records from the record categories or My Tags. The selection of items can be made by clicking the filter icon in the upper right-hand corner of the container.




The user can filter the information on My Dashboard in two ways:

1. By date: changing the date range in the Daily Brief section
2. By country/region: selecting from the interactive map of available countries or the list of regions located in the upper right corner of the container



PORTAL PROFILES & MY RADAR

MAR allows the user to create a portal according to specific requirements and interests. With the Portal Profile feature, the user can create up to **5 different profiles** to create My Radar.



PROFILE CREATION – MAR CUSTOMIZED BY THE USER

PORTAL PROFILES

EDIT PROFILE 1

CLEAR

Migraine

REGIONS: EUROPE, CEE, CIS AND BALTIC, AMERICA, ASIA AND AUSTRALIA, GLOBAL

OTHER: Acute Migraine

SOURCES: Companies, Media, Agency, Chambers, MoH/Gov/Payer, Other

EDIT PROFILE 2

CLEAR

Lung Cancer

REGIONS: EUROPE

OTHER: lung cancer, advanced lung cancer, advanced non-small cell lung cancer, ALK-positive advanced non-small-cell lung cancer, metastatic non-small cell lung cancer, non small cell lung cancer

SOURCES: Companies, Media, Agency, Chambers, MoH/Gov/Payer, Other

EDIT PROFILE 3

CLEAR

EDIT PROFILE 4

CLEAR

EDIT PROFILE 5

CLEAR

CLOSE

EXPORT

MAR allows five different My Radar profiles and you can easily switch between them by clicking the “My Radar” button.

MY CUSTOM PROFILES

▶ MIGRAINE

▶ LUNG CANCER

CLOSE

PROFILE CREATION

1) Enter your unique profile name

2) Enter your country/ies of interest (drop-down selection available) or select an entire region. You can mix both: e.g., Europe as region and US as the country

3) Enter "Your Interests", the information you would like to receive on My Radar - substances, brands, indications, agency names, etc. Customize based on existing tags in the repository. You can also leave this field blank and proceed to advanced settings below.

4) Advanced settings are based on close relationships between three values: indication, brand, and substance. As a result of the monitoring, you will receive information if there is an association with a brand or substance in the database for a particular indication (e.g., drug evaluation process by NICE or HAS). You do not need to enter advanced settings; you can rely only on the field in "Your Interest", which has a wider results scope.

5) Select the sources of information from which you want to receive records for. For example, do you want to receive data only from HTA agencies (select "Agency")? Or, select all to receive information from over 600 sources.

6) Finally, don't forget to "Apply all Settings" to save your profile or select "Apply & Run" to view the results and to save.

PROFILE 2

Lung Cancer

COUNTRIES

Select region or countries

EUROPE CEE, CIS AND BALTIC AMERICA ASIA AND AUSTRALIA GLOBAL

YOUR INTERESTS

Select substances, brands, companies, indications or whatever you want

LUNG CANCER ADVANCED LUNG CANCER ADVANCED NON-SMALL CELL LUNG CANCER
ALK-POSITIVE ADVANCED NON-SMALL-CELL LUNG CANCER
METASTATIC NON-SMALL CELL LUNG CANCER NON SMALL CELL LUNG CANCER

Your interests AND advanced settings

ADVANCED SETTINGS

((indication=indication2 OR ... OR indication=indicationn) AND ((brand=brand2 OR brand=brandn) OR (substance=substance2 OR ... OR substance=substancen)))

INDICATION

Select indications

BRAND

Select brands

SUBSTANCE

Select substances

SOURCES

Select sources of information

Companies Media Agency Chambers MoH/Gov/Player Other

APPLY ALL SETTINGS APPLY & RUN

SOURCES OF INFORMATION

The user can see sources of information from the selected sources category. Click on the category name and a list of the sources will appear below. If the user wants to add a new resource not currently available to be monitored daily by our experts, they may request this through “Ask an Expert”.

SOURCES

Select sources of information

☒ Companies

☒ Media

☒ Agency

☒ Chambers

☒ MoH/Gov/Payer

☒ Other

APPLY ALL SETTINGS

APPLY & RUN

SOURCES LIST (AGENCY)

Australia	Medical Services Advisory Committee (MSAC)
Australia	Pharmaceutical Benefits Scheme (PBS)
Austria	Austrian Institute for Health Technology Assessment
Austria	Institute for Health Technology Assessment
Belgium	KCE - Belgian HC Knowledge Centre
Bosnia and Herzegovina	Agency for Medicinal Products and Medical Devices
Bulgaria	Bulgarian Drug Agency
Bulgaria	Drug Agency
Canada	Canadian Agency for Drugs and Technologies in Health
Canada	National Institute of Excellence in Health and Social Services (INESSS)
Croatia	Agency for Quality and Accreditation in Health and Social Welfare
Czech Republic	State Institute for Drug Control (SUKL)
Denmark	Danish Medicines Agency
Estonia	Health Board
Estonia	State Agency of Medicines
EU	AdHopHTA
EU	Council of the European Union
EU	EUnetHTA
EU	European Commission
EU	European Medicines Agency
EU	Heads of Medicines Agencies (HMA)

MY RADAR

MY CUSTOM PROFILES

▶ MIGRAINE

▶ LUNG CANCER

CLOSE

Load profiles by clicking “My Radar” and selecting the customized profile.

Once the profile is loaded, the most recent records for the loaded settings will be displayed. If the user wants to track historical data, go to Archive and search using the date range.

The user’s selected profile appears next to the My Radar icon.

The screenshot displays the Market Access Radar interface. At the top, the 'MY RADAR' icon is highlighted with a red box, and the text 'Selected profile: LUNG CANCER' is shown next to it. Below this, the interface is divided into several sections:

- Archive:** Shows a list of records for 'LUNG CANCER'. The first record is dated '14 Oct 2021' and mentions 'Switzerland: Swissmedic published Public Summary SwissPAR for Tepmetko (tepotinib) for the treatment of non-small cell lung cancer (NSCLC) with MET exon 14 skipping gene changes'. The second record is dated '07 Oct 2021' and mentions 'Germany: IQWiG completes assessment according to §35a Social Code Book V of osimertinib in the treatment of adult patients with stage IB to IIIA non-small cell lung cancer (NSCLC) with exon 19 deletion or exon 21 substitution mutation (L858R) of the epidermal growth factor receptor (EGFR) after complete tumour resection'.
- Your Regional Interest:** A world map showing various regions highlighted in blue.
- Market Access Catalyst:** A list of news items related to market access, including safety updates and regulatory decisions.
- My Tags:** A section showing tags for 'MIGRAINE' and 'LUNG CANCER'.

In My Radar mode, the user can navigate through Daily Brief and Archive, which will display data according to the settings of the loaded profile.

If the user wants to return to the default MAR and exit from the loaded profile, click on the MAR logo in the left-hand corner.

MY RADAR

PORTAL PROFILES

EDIT PROFILE 1

CLEAR

Migraine
REGIONS: EUROPE, CEE, CIS AND BALTIC, AMERICA, ASIA AND AUSTRALIA, GLOBAL
OTHER Acute Migraine
SOURCES: Companies, Media, Agency, Chambers, MoH/Gov/Payer, Other

EDIT PROFILE 2

CLEAR

Lung Cancer
REGIONS: EUROPE
OTHER lung cancer, advanced lung cancer, advanced non-small cell lung cancer, ALK-positive advanced non-small-cell lung cancer, metastatic non-small cell lung cancer , non small cell lung cancer
SOURCES: Companies, Media, Agency, Chambers, MoH/Gov/Payer, Other

EDIT PROFILE 3

CLEAR

EDIT PROFILE 4

CLEAR

EDIT PROFILE 5

CLEAR

CLOSE

EXPORT

1M

3M

6M

The user can export all results from all of his/her profiles into an **Excel (.xlsx)** file.

Select the data range of export, from 1 month up to 6 months from the present date.

REPORT SETTINGS

The user receives the Report via email daily or weekly and contains your personal customizations! These selections can be made in the Report settings.

The user can also create the content of their Report, which will consistently show only the information customized to receive based on the user’s profiles. If the user does not create unique profiles, MAR will send the records (as Default) added to the database on a given day or week.

REPORT SETTINGS



Receive report daily or weekly by email

Migraine	<input checked="" type="checkbox"/> DAILY	<input type="checkbox"/> WEEKLY	<input type="checkbox"/> NEVER
Lung Cancer	<input checked="" type="checkbox"/> DAILY	<input type="checkbox"/> WEEKLY	<input type="checkbox"/> NEVER
DEFAULT	<input checked="" type="checkbox"/> DAILY	<input type="checkbox"/> WEEKLY	<input type="checkbox"/> NEVER

APPLY ALL SETTINGS



CONTACT

Want to know more?

Contact us

contact@marketaccess-radar.com